Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic compositions of rifamycins and uses thereof

a technology of ophthalmic compositions and rifamycin, which is applied in the field of pharmaceutically acceptable compositions, can solve the problems of loss of visual acuity, loss of vision in the center of the visual field (the macula), and difficulty or inability to read or recognize faces

Inactive Publication Date: 2019-08-22
SERIZAWA HIROAKI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about pharmaceutical compositions that can be applied to the eye to treat various ocular diseases and conditions. The compositions contain rifamycin compounds, such as rifampicin, rifabutin, rifapentine, or rifaximin. These compounds have been found to have beneficial effects on reducing neovascularization in the retina, age-related macular degeneration, and protecting retina ganglion cells and brain damage. The patent also describes different formulations of the compositions, such as eye drops, injectables, and pills, and provides information on their pH and physiological salt concentration. Overall, this patent provides a technical solution for developing effective treatments for ocular diseases and disorders.

Problems solved by technology

Loss of visual acuity is a common problem associated with aging and with various diseases of the eye such as macular degeneration, ocular histoplasmosis syndrome, myopia, diabetic retinopathy and inflammatory diseases all of which result from neovascularization in the cornea, retina or choroid.
Age-Related Macular Degeneration (AMD) is a common eye condition which usually affects older adults and results in a loss of vision in the center of the visual field (the macula) due to retinal damage.
Although some peripheral vision remains, it is difficult or impossible to read or recognize faces.
AMD is a leading cause of blindness among people older than 65 years and is caused by abnormal development of blood vessels behind retina.
However, intravitreal injection is a process that requires great precision, because it is performed with the help of a needle under local anesthesia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic compositions of rifamycins and uses thereof
  • Ophthalmic compositions of rifamycins and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Formulation of Rifamycin Compounds

[0084]The active ingredient, i.e. rifamipicin, rifabutin, rifapentine, rifalazil or rifaximin is dissolved in saline or water and a surfactant such as polysorbate 80, tween 80 or tween 20 is added and mixed. Further, various additives such as glycerin, xanthan gum, hydroxypropylmethylcellulose (HPMC), cyclodextrin derivatives such as hydroxypropyl-β-cyclodextrin, isotonic agents such as such as sodium chloride, potassium chloride or sodium bisulfate, preservative such as disodium EDTA or methylparaben, anti-oxidant such as ascorbic acid are optionally added and mixed to form a clear solution. The solution is optionally filtered to remove particulate matter and the pH is adjusted by adding an acid such as hydrochloric acid or a base such as sodium chloride to obtain the desired pH.

example 2

[0085]16 different formulations were prepared for topical eye drop application of rifampicin, as disclosed in Tables 1-3. The formulations of Example 1A and Example 6A were used in the following studies.

[0086]The following eye drop formulations were prepared at room temperature (Tables 1 and 2), and Rifampicin was added to the eye drop formulations to the final concentrations listed:

TABLE 1ExampleExampleExampleExampleExample1A2A3A4A5ApH of input buffer (50 mM BoricpH 8.7pH 8.7Acid-Borax)pH of input buffer (100 mMpH 8.3pH 8.3pH 8.3Boric Acid-NaOH)Final concentrations of input 10 mM 10 mM20 mM25 mM25 mMbuffersFinal pH detected after additionpH 7.64pH 7.37pH 8.01pH 8.30of RifampicinNaCl*150 mM150 mM0.9%0.9%0.9%Tween 80* 0.5%0.5%0.5%0.5%0.5%EDTA* 0.1%0.1%0.1%0.1%0.1%Benzalkonium chloride*0.01%0.01% 0.01% 0.01% 0.01% Rifampicin*0.25%0.5%0.5%  1%0.5%*Final concentrations

TABLE 2Exam-Exam-Exam-Exam-Exam-ple 6Aple 7Aple 8Aple 9Aple 10ApH of input bufferpH 8.7pH 8.7pH 8.5pH 8.5pH 8.3(50 mM Bo...

example 3

[0090]Rifampicin was delivered to retina by topical eye drop application. 0.25% rifampicin eye drop formulation was used for the studies. It showed good delivery efficiency, and retina tissue got micro gram concentrations of rifampicin per g of tissue by the eye drop application.

[0091]Four male Sprague-Dawley rats (250-300 g) were used to determine retina exposure levels of rifampicin following applications of eye drops. Two rats received 3 drops of an eye drop formulation (0.25% Rifampicin) which is presented as Example 1A listed in Table 1 in each eye under isoflurane sedation. The remaining two rats received the same applications, but 10 drops, to each eye under isoflurane sedation. A single drop contained 5 micro L of the formulation, and applications of each drop had 30 min interval. After the eye drop application, retinas were extracted under a dissection microscope. In addition, “Non-treatment” negative control was taken, and retina was extracted from two rats without any tre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
viscosityaaaaaaaaaa
viscosityaaaaaaaaaa
viscosityaaaaaaaaaa
Login to View More

Abstract

Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

Description

REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Non-Provisional application Ser. No. 15 / 327,951 filed Jan. 20, 2017, which is a National Stage Entry of International PCT Application No. PCT / US15 / 41196 filed Jul. 20, 2015, which claims priority to U.S. Provisional Application Ser. No. 62 / 027,189 filed Jul. 21, 2014, 62 / 136,222 filed Mar. 20, 2015, and 62 / 174,884 filed Jun. 12, 2015, the content of each of which is incorporated herein in its entirety by reference.FIELD OF THE INVENTION[0002]Provided herein are pharmaceutically acceptable compositions or compositions suitable for topical administration to an eye, the composition comprising a therapeutically-effective amount of an antimicrobial agent, which, in a preferred embodiment comprises a rifamycin derivative, methods for their preparation, and methods for their use in treating various disorders.BACKGROUND[0003]Loss of visual acuity is a common problem associated with aging and with various disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5383A61K31/496A61K9/00A61K9/08A61K31/435A61K47/18A61K47/02A61K47/10A61K47/14A61K47/26
CPCA61K31/5383A61K31/496A61K9/0048A61K9/08A61K31/435A61K47/183A61K47/02A61K47/10A61K47/14A61K47/26A61K9/0019A61P25/00A61P27/02
Inventor SERIZAWA, HIROAKI
Owner SERIZAWA HIROAKI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com